文献速递基础与转化研究临床试验与 GCP组学、生物样本库与精准医学

动员抗原呈递肥大细胞治疗抗PD-1耐药三阴性乳腺癌:一项2期试验

Mobilizing antigen-presenting mast cells in anti-PD-1-refractory triple-negative breast cancer: a phase 2 trial.
PubMed 文献 · Nat Med · 2025-06-25

研究整合44例初治三阴性乳腺癌患者单细胞转录组,发现瘤内肥大细胞异质性与PD-1阻断临床获益相关,并在484例患者中验证乳腺组织抗原呈递肥大细胞(apMC)高水平与抗PD-1疗效增强相关。机制上apMC多位于三级淋巴结构内,能有效呈递与交叉呈递抗原并表达共刺激分子。色甘酸钠可动员apMC介导的T细胞免疫,使肿瘤对PD-1阻断敏感。随后在抗PD-1耐药转移性三阴性乳腺癌女性患者中开展2期试验,报告色甘酸钠联合抗PD-1骨架组结果,该组预设主要终点达到,确认客观缓解率为50.0%。

要点

  • 44例初治TNBC单细胞转录组提示瘤内肥大细胞异质性与PD-1阻断临床获益相关。
  • 484例TNBC验证乳腺组织apMC高水平与抗PD-1疗效增强相关。
  • 2期试验色甘酸钠联合抗PD-1骨架组确认客观缓解率50.0%,预设主要终点达到。

核心结论

  • 研究定义肥大细胞在肿瘤免疫控制中的关键作用,并确定靶向apMC克服抗PD-1耐药的策略。
  • 研究提出反向转化框架,为精准免疫肿瘤学提供概念进展并直接关联临床治疗。

研究设计与样本

  • 研究整合44例初治三阴性乳腺癌患者单细胞转录组,分析瘤内肥大细胞异质性与PD-1阻断临床获益的关联。
  • 在484例三阴性乳腺癌患者中进行独立平行验证,评估乳腺组织apMC水平与抗PD-1疗效的关系。
  • 开展2期临床试验(ClinicalTrials.gov标识NCT05076682),在抗PD-1耐药转移性三阴性乳腺癌女性患者中报告色甘酸钠联合抗PD-1骨架组结果。

主要发现

  • 44例初治TNBC单细胞转录组揭示患者内肥大细胞异质性与PD-1阻断临床获益相关。
  • 484例TNBC独立平行验证显示,乳腺组织apMC高水平与抗PD-1疗效增强相关。
  • apMC多位于三级淋巴结构内,能有效呈递与交叉呈递抗原并表达共刺激分子。
  • 条件性删除肥大细胞抗原呈递机制可削弱肿瘤反应性T细胞。
  • 色甘酸钠被鉴定为可动员apMC介导的T细胞免疫并使肿瘤对PD-1阻断敏感。

关键数值与推荐

  • 2期试验色甘酸钠联合抗PD-1骨架组确认客观缓解率为50.0%。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The central challenge in triple-negative breast cancer (TNBC) immunotherapy is to identify novel mechanism-derived strategies for anti-programmed death-1 (PD-1) resistance and efficiently assess their efficacy and safety in humans. Understanding the intricate heterogeneity of the tumor microenvironment and its impact on treatment could guide the initiation of proof-of-concept clinical trials. Here, integrating single-cell transcriptome of 44 treatment-naive patients with TNBC, we unveiled an association between intrapatient mast cell heterogeneity and clinical benefit of PD-1 blockade. Upon independent parallel validation in 484 patients with TNBC, high levels of breast tissue antigen-presenting mast cells (apMCs) were associated with enhanced anti-PD-1 efficacy. Mechanistically, apMCs largely located within tertiary lymphoid structures and were efficient in performing presentation and cross-presentation of antigens and expressed co-stimulatory molecules. Conditional deletion of antigen-presenting machinery in mast cells dampened tumor-reactive T cells. A widely prescribed allergy medication, cromolyn, was identified to mobilize apMC-mediated T cell immunity and sensitize tumors to PD-1 blockade. We subsequently initiated a phase 2 clinical trial in female patients with anti-PD-1-refractory metastatic TNBC. Here we report the results of the cromolyn arm (cromolyn plus anti-PD-1 backbone). The prespecified primary endpoint of this arm was met, with a confirmed objective response rate of 50.0%. Our study defines a crucial role of mast cells in cancer immune control, identifies an apMC-directed approach to overcome anti-PD-1 resistance and highlights a reverse-translational framework that offers conceptual advances in precision immuno-oncology with direct implications for clinical therapy. ClinicalTrials.gov identifier: NCT05076682 .

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Wu SY, Jin X, Liu Y, et al. Mobilizing antigen-presenting mast cells in anti-PD-1-refractory triple-negative breast cancer: a phase 2 trial. Nat Med. 2025. PMID: 40563015. doi:10.1038/s41591-025-03776-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。